Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873820 | 0.80 | HTR2C (0.48) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29356733 | 0.75 | MEN1 (0.60) | HTR2CTAAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL11639387 | 0.75 | MEN1 (0.60) | HTR2CTAAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6237708 | 0.74 | SLC6A2 (0.46) | GRIN2BGRIN1CYP24A1HTR2CHTR1A | |
| SCHEMBL7744268 | 0.72 | GRIN2B (0.47) | GRIN2BGRIN1HTR2C | |
| SCHEMBL6491638 | 0.72 | HTR2C (0.72) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17965635 | 0.71 | HTR2C (0.50) | GRIN2BGRIN1HTR2CCHRNB2CHRNB4 | |
| SCHEMBL10387927 | 0.71 | HTR2C (0.50) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5871586 | 0.71 | TAAR1 (0.46) | HTR2CTAAR1 | |
| SCHEMBL5778167 | 0.69 | HTR2C (0.49) | HTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| EP-1507763-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097607-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | GRIN2B 3114/4885GRIN1 2013/4885CYP24A1 1050/4885 |
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | GRIN2B 1394/4885GRIN1 1832/4885CYP24A1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.